Filter By Category
Archives
Share on -
CAMIDANLUMAB TESIRINE
Generic Name: CAMIDANLUMAB TESIRINE
ABSTRACT -
Camidanlumab tesirine (ADCT-301) is an antibody-drug conjugate (ADC) consisting of an anti-CD25 antibody conjugated to the pyrrolobenzodiazepine (PBD) dimer toxin tesirine. It targets CD25 (IL-2 receptor alpha) overexpressed on Hodgkin lymphoma and other haematological malignancies, delivering DNA-crosslinking cytotoxicity selectively to CD25+ tumour cells. Phase I data demonstrated activity in relapsed/refractory Hodgkin lymphoma.
DOSAGE -
Intravenous infusion; 45 µg/kg every 3 weeks was a key dose in Phase I; dosing optimised in Phase II studies.
SIDE EFFECTS -
- Maculopapular rash
- Peripheral oedema
- Fatigue
- Fever
- Pleural effusion
ALLERGIC REACTIONS -
These symptoms may indicate an allergic reaction and require immediate medical attention.
- Infusion-related hypersensitivity
- Severe skin reactions
- Anaphylaxis
- Urticaria
DRUG INTERACTIONS-
- Avoid other DNA-damaging agents concurrently — additive genotoxicity
- Caution with corticosteroids pre-used for irAE management
- CYP interactions of PBD payload under investigation
PREAUTONS–
- Dermatological monitoring mandatory — PBD class causes skin toxicity
- Monitor for effusions (pleural, pericardial)
- Effective contraception required
- Male patients: consider sperm banking prior to treatment
WARNINGS –
- PBD-associated severe skin toxicity including photosensitivity — avoid sun exposure
- Fluid accumulation (oedema, effusions) can require diuresis or drainage
- Embryo-foetal toxicity — contraindicated in pregnancy
Share on -
. Developed by